Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR …
…, M Dougados, TK Kvien, EM Mola… - Annals of the …, 2010 - ard.bmj.com
Objectives To assess the efficacy and safety of synthetic disease-modifying antirheumatic
drugs (DMARDs) in adults with rheumatoid arthritis (RA)—a first step in a European League …
drugs (DMARDs) in adults with rheumatoid arthritis (RA)—a first step in a European League …
Septic arthritis
M García-Arias, A Balsa, EM Mola - Best practice & research Clinical …, 2011 - Elsevier
This article presents a review of the current approach to diagnostic and therapeutic conditions
of septic arthritis. Acute septic arthritis is an uncommon, but potentially fatal, emergency. …
of septic arthritis. Acute septic arthritis is an uncommon, but potentially fatal, emergency. …
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind …
…, JP de Jager, A Gough, J Kalden, M Malaise, EM Mola… - The Lancet, 2004 - thelancet.com
Background Etanercept and methotrexate are effective in the treatment of rheumatoid arthritis
but no data exist on concurrent initiation or use of the combination compared with either …
but no data exist on concurrent initiation or use of the combination compared with either …
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active‐surveillance …
…, L Carmona, VR Valverde, EM Mola… - … : Official Journal of …, 2003 - Wiley Online Library
Objective The long‐term safety of therapeutic agents that neutralize tumor necrosis factor (TNF)
is uncertain. Recent evidence based on spontaneous reporting shows an association …
is uncertain. Recent evidence based on spontaneous reporting shows an association …
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
…, SF Luo, R Kurucz, G Maciel, EM Mola… - Annals of the …, 2014 - ard.bmj.com
Background Patients with rheumatoid arthritis (RA) are at increased risk of developing
comorbid conditions. Objectives To evaluate the prevalence of comorbidities and compare their …
comorbid conditions. Objectives To evaluate the prevalence of comorbidities and compare their …
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including …
…, S Lohmander, B Mazieres, EM Mola… - Annals of the …, 2000 - ard.bmj.com
BACKGROUND Osteoarthritis (OA) is the most common joint disease encountered throughout
Europe. A task force for the EULAR Standing Committee for Clinical Trials met in 1998 to …
Europe. A task force for the EULAR Standing Committee for Clinical Trials met in 1998 to …
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
…, D Montero, E Pascual‐Gómez, EM Mola… - Arthritis & …, 2005 - Wiley Online Library
Objective To investigate the impact of official recommendations regarding the management
of latent tuberculosis (TB) infection on the rate of active TB in patients receiving treatment …
of latent tuberculosis (TB) infection on the rate of active TB in patients receiving treatment …
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year …
…, T Sheeran, PP Tak, PG Conaghan, EM Mola… - Annals of the …, 2013 - ard.bmj.com
Objective In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare
the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy. Methods …
the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy. Methods …
A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects
…, M Figueroa, J Belzunegui, EM Mola… - Annals of the …, 2008 - ard.bmj.com
Objective: Open label studies have suggested that tumour necrosis factor (TNF) antagonists
led to sustained improvement and corticosteroid sparing effect in patients with giant cell …
led to sustained improvement and corticosteroid sparing effect in patients with giant cell …
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
…, J Kalden, M Leirisalo-Repo, EM Mola… - Annals of the …, 2004 - ard.bmj.com
Objective: A double blind, randomised, placebo controlled study to evaluate the safety and
efficacy of etanercept to treat adult patients with ankylosing spondylitis (AS). Methods: Adult …
efficacy of etanercept to treat adult patients with ankylosing spondylitis (AS). Methods: Adult …